We can't find the internet
Attempting to reconnect
16003.1 PFLS-LS
SwissBody-enabled small molecule drug discovery for neurotransmitter/ion transporters and G protein-coupled receptors.
Zusammenfassung
SwissBody-enabled small molecule drug discovery for neurotransmitter/ion transporters and G protein-coupled receptors.
Weitere Texte
Abstract
Neurotransmitter/ion transporters and G protein-coupled receptors are druggable targets, but are suffering from a very high compound attrition rate. Recently, biophysical assays and structure-based drug design have enabled to overcome this hurdle but their development is time-consuming. Now, we aim at improving this process using synthetic camelid single domain antibody fragments (SwissBodies). In a novel and fast procedure we generate tailored SwissBodies to accelerate the development of novel biophysical tools and reduce compound attrition rates.
Beteiligte
Roger Dawson
Wirtschaftspartner
Roger.dawson@roche.com
Hoffmann-La Roche AG Roger Dawson Grenzacherstrasse 124 4070 Basel BS CH
Markus Seeger
Kontaktperson
m.seeger@imm.uzh.ch
Universität Zürich Markus Seeger Gloriastrasse 30/32 8006 Zürich ZH CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2014-04-30
- Enddatum
- 2017-08-31
- Bewilligte Gesamtkosten
- CHF 715596.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%